| T cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia |
|
International Journal of Hematology |
Aplastic Anemia |
| Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
|
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
| Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study |
|
Journal of Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| PNH and complement gene variants |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
